aside from taking Celgene into the field of multiple sclerosis with oral drug ozanimod, the compound could become an important new drug in ulcerative colitis. Ozanimod is an oral medicine and ...

Otezla (apremilast) is Celgene's attempt to break into the immunology field currently dominated by the TNF blocker drugs, led by AbbVie's Humira. The oral treatment has a novel mechanism ...

The drugs treat conditions such as diabetes and ... Pfizer and Bristol Myers Squibb (parent company of the Celgene Corp.) will all be asked to negotiate with Medicare for a second year in a ...

Celgene (Warren, NJ), a developer of chirally pure drugs, agreed on June 30 to purchase gene-regulation firm Signal Pharmaceuticals (San Diego, CA) for $200 million in an all-stock deal.

UMB Financial plans to refile a $6.4 billion against Bristol-Myers Squibb by shareholders owning contingent value rights over ...

Drugmaker Bristol-Myers Squibb is willing to part ways with one of Celgene's most profitable drugs in order to get the companies' $74 billion deal approved by regulators. And investors don't like ...

Celgene has acquired Gloucester Pharmaceuticals ... Merck) (see Nature Rev. Drug Discov. 6, 21–22; 2007) by the FDA in October 2006. Romidepsin and vorinostat have very different chemical ...

Revlimid, the big-selling multiple myeloma drug acquired in Bristol’s buyout of Celgene, will face a new slate of generics in March and then a full generic market in 2026, Boerner said.